Shikeda masks slow second quarter for buyouts
The money spent on biopharma acquisitions in the second quarter looks huge, but most of the total is down to one deal.
First-quarter acquisition activity lifts hopes for a big year
After a slow 2017, first-quarter biopharma acquisition activity could signal a turnaround.
Biotech gets creative about the pay cheque
Amid a backlash over the high prices of advanced therapies, biotech companies are coming up with new payment models.
Corporate venture firms – dedicated followers of fashion?
Eagerly pursuing all the latest fads and trends.
Does Roche have the haemophilia X factor?
Experts expect Roche's Hemlibra to dominate the inhibitor patient population, but to be a big deal it will need to impress in non-inhibitor patients, too.